Welcome to our dedicated page for Cellyan Biotechnology Co SEC filings (Ticker: HKPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD), formerly Hong Kong Pharma Digital Technology Holdings Limited, provides access to the company’s regulatory disclosures as a foreign private issuer in the healthcare and pharmaceutical retailers space. These filings, including Form 6-K reports and registration statements, document key information about HKPD’s OTC pharmaceutical cross-border e-commerce supply chain services and OTC pharmaceutical cross-border procurement and distribution businesses conducted through its Hong Kong subsidiaries.
Through its filings, the company presents unaudited condensed consolidated financial statements, including statements of profit or loss and other comprehensive income, statements of financial position, and details on revenues from supply chain services, procurement and distribution, and consignment sales and other revenue. Investors can review disclosures on cost of revenues, selling, general and administrative expenses, operating profit, net profit, assets such as inventories and right-of-use assets, and liabilities including bank loans and lease liabilities. Annual and interim reports, when filed on forms such as 20-F or related submissions, provide broader context on business operations and risk factors.
Form 6-K filings also capture corporate governance and capital markets events, such as the closing of the initial public offering and commencement of trading on the Nasdaq Capital Market under the ticker HKPD, management changes, appointment of independent directors, and the results of annual general meetings of shareholders. These reports describe shareholder approvals for increases in authorized share capital, re-designation of ordinary shares into Class A and Class B ordinary shares, reverse share split and share consolidation parameters, adoption of a fourth amended and restated memorandum and articles of association, share repurchases and related issuance of Class B ordinary shares, and adoption of an equity incentive plan.
On Stock Titan, HKPD’s filings are updated in line with submissions to the SEC’s EDGAR system. AI-powered summaries help explain the contents of lengthy filings, highlight changes in capital structure, governance, and financial performance, and make it easier to identify items such as quarterly and annual financial reporting, share capital changes, and other material events. Users can use this page to quickly understand how regulatory disclosures relate to Cellyan Biotechnology’s OTC pharmaceutical cross-border supply chain and procurement activities and to monitor the company’s reported developments over time.
Cellyan Biotechnology Co., Ltd reported that Nasdaq has notified the company its Class A ordinary shares failed to meet the minimum bid price requirement, as the closing bid stayed below US$1.00 for 30 consecutive business days from November 26, 2025 through January 9, 2026. The notice does not immediately affect the listing and the shares continue to trade on Nasdaq under the ticker HKPD.
The company has 180 calendar days, until July 13, 2026, to regain compliance by having its closing bid at or above US$1.00 for at least ten consecutive business days. If it still does not comply by that date, it may qualify for an additional 180-day grace period if other Nasdaq listing standards are met and it indicates plans to cure the deficiency, potentially including a reverse share split completed at least ten business days before the relevant deadline.
Hong Kong Pharma Digital Technology Holdings Limited reported that shareholders approved all nine proposals at its 2025 annual general meeting. Of 11,000,000 ordinary shares outstanding as of November 14, 2025, holders of 7,185,876 shares, or about 65.32% of the votes, were present in person or by proxy.
Shareholders elected the full director slate and approved a major share capital reorganization. All issued ordinary shares were redesignated as Class A ordinary shares with one vote per share, while 60,000,000 authorized but unissued shares were redesignated as Class B ordinary shares with 50 votes per share, leaving authorized capital at US$1,000,000 split into 940,000,000 Class A and 60,000,000 Class B shares.
They also authorized the board to carry out a reverse share split and share consolidation at a ratio between one-for-ten and one-for-one hundred, adopted a Fourth Amended and Restated Memorandum and Articles of Association, and approved a repurchase to be funded by a fresh issue of 7,150,000 Class B ordinary shares so that issued share capital remains unchanged after the transaction.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reported that it will hold its annual general meeting of shareholders on December 12, 2025 at 10:00 a.m. Hong Kong Time (December 11, 2025 at 9:00 p.m. Eastern Time). The meeting will take place at the company’s principal office in Yau Tong, Kowloon, Hong Kong.
The company is providing shareholders with a proxy statement and notice of meeting, a form of proxy card, a proposed 2025 Equity Incentive Plan, and a form of fourth amended and restated memorandum and articles of association, all of which are furnished as exhibits and incorporated by reference.
Hong Kong Pharma Digital Technology Holdings Limited reported major leadership changes. On October 6, 2025, the board accepted the immediate resignations of its Chief Executive Officer, Executive Director, and Chief Financial Officer, all citing personal reasons and no disagreements with the company or board. Earlier, on April 30, 2025, the Chief Operating Officer also resigned for personal reasons.
The board simultaneously rebuilt the senior team by appointing Chenyu Liang as Director and Chief Executive Officer, Shu Liu as Chief Financial Officer, and Zifeng Wang as Chief Strategy Officer, each with prior management and industry experience. They entered employment agreements providing annual base salaries of HKD100,000 for Mr. Liang and Ms. Liu and HKD70,000 for Mr. Wang.
Hong Kong Pharma Digital Technology Holdings Limited reported that its board appointed Mr. Zhou Mike Yao as an independent director effective September 9, 2025, and named him to the board’s nomination committee. Mr. Zhou, aged 34, has experience in investment, capital markets and corporate development, including roles at Norwich Capital Limited, MYZ Corporate Relations Ltd., Direct Communication Solutions Inc. and Explorex Resource Inc. The board determined he meets the Nasdaq definition of an independent director.
The company will pay Mr. Zhou annual compensation of HK$100,000, payable quarterly in arrears, and has entered into its standard indemnification agreement for directors to protect him in connection with his board service. The board notes that there are no related party transactions requiring disclosure and states its belief that Mr. Zhou will bring broad management experience to the company.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reports fiscal results and an extensive risk disclosure in its Form 20-F. The company completed a 1-for-10 share subdivision that increased issued shares to 11,000,000 (11,000 par units reported) and completed an IPO. Consolidated revenue lines shown in the filing include totals such as $20,313,818 and operating segments with revenue amounts like $7,511,591 and $6,217,798. The company recorded a net profit of $1,329,717 for one reported year and basic earnings per share of $0.180. Major shareholders and insider holdings are disclosed: the group of directors and officers hold 56.77% beneficially; Lap Sun Wong is identified as CEO and Chairman and retains controlling voting power. The filing lists extensive regulatory, geopolitical and operational risks, including concentration of customers and suppliers, IT and data governance risks, potential impact of PRC/Hong Kong regulation, possible Nasdaq listing pressures (past share price under $1 and delisting risk), and dependence on HK subsidiaries for cash distributions. The report also discloses material leases, licenses, and bank borrowings and notes key operating costs such as transportation and storage.